Sildenafil Citrate Powder, For Suspension
Product Images NDC 70710-1716

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 70710-1716). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals (usa) Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 01)

An instructional diagram showing a graduated cylinder filled with liquid on the left, a bottle with liquid at the center, and a syringe marked with measurements on the right, illustrating the process of measuring and withdrawing liquid medication for oral suspension dosage.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 02)

An instructional diagram showing three steps for preparing oral suspension from a bottle: pressing down and turning the cap to open, shaking the bottle vertically with an up-and-down motion, and a stopwatch indicating timing, possibly for shaking duration or wait time.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 03)

An instructional diagram displaying a graduated cylinder with volume markings and a syringe with volume markings labelled 'x 1', alongside an open medicine bottle containing suspension. The diagram likely illustrates measuring and administering the oral suspension of Sildenafil Citrate powder for suspension.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 04)

An instructional illustration showing steps for preparing an oral suspension from a bottle. The sequence depicts removing and twisting off the cap, shaking the bottle up and down, and a stopwatch indicating a wait time of approximately 30 seconds.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 05)

An instructional illustration showing how to assemble and use a dropper with a bottle. One image depicts placing the dropper cap onto the bottle opening, and the other shows twisting the dropper cap to secure it on the bottle.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 06)

A step plot showing estimated cumulative mortality rate (%) over time (years) for three dose groups labeled High Dose, Medium Dose, and Low Dose. The graph includes a table indicating the number of subjects at risk at multiple time points for each dose group.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 07)

Chemical structure of Sildenafil Citrate showing its molecular framework with labeled functional groups, including nitrogen-containing rings, sulfonyl group, and citrate moiety. This diagram illustrates the arrangement of atoms and bonds in the active ingredient Sildenafil Citrate.*

FDA Label Image

Figure 7 (9e802fb6 2a6b 4d5e B292 8a3c31e26076 08)

A forest plot chart showing fold changes with 90% confidence intervals for AUC and Cmax comparing various interacting drugs relative to Sildenafil Citrate alone. The chart lists drugs like Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir, with associated recommendations regarding dose adjustments.*

FDA Label Image

Figure 8 (9e802fb6 2a6b 4d5e B292 8a3c31e26076 09)

A chart showing fold change and 90% confidence intervals in pharmacokinetic parameters for various interacting drugs with sildenafil. The x-axis represents change relative to interacting drug alone, with a vertical line at 1. The chart lists drugs such as Acenocoumarol, Aspirin, Atorvastatin, Bosentan, Doxazosin (three strengths), Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide, alongside recommendations on dose adjustments. Most interactions show no dose adjustment needed, except for Ritonavir where coadministration is not recommended.*

FDA Label Image

Figure 9 (9e802fb6 2a6b 4d5e B292 8a3c31e26076 10)

A line chart depicting mean change from baseline in meters over weeks 4, 8, and 12 of a study. The x-axis represents the week of study, and the y-axis represents change from baseline in meters. The graph compares placebo and Sildenafil Citrate doses of 20 mg TID, 40 mg TID, and 80 mg TID, showing data points with error bars over time.*

FDA Label Image

Figure 10 (9e802fb6 2a6b 4d5e B292 8a3c31e26076 11)

A horizontal forest plot showing placebo-corrected change in 6-minute walk distance (meters) for Sildenafil 20 mg TID compared to placebo. It includes subgroups categorized by baseline walk distance, etiology of pulmonary arterial hypertension (PAH), functional class, gender, age, mean pulmonary arterial pressure (PAP), and pulmonary vascular resistance index (PVRI). Each subgroup displays the number of participants and confidence intervals for the treatment effect.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 12)

A line graph comparing the percentage of subjects without a clinically worsening event over a period of 112 days from randomization, showing two curves labeled Sildenafil and Placebo. The y-axis represents the percentage without worsening, and the x-axis shows days from randomization. The Sildenafil group maintains a higher percentage over time compared to the Placebo group.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 13)

A line graph showing the mean change from baseline in meters over 12 weeks for Sildenafil Citrate at doses of 1 mg TID, 5 mg TID, and 20 mg TID. The y-axis represents change from baseline (meters), and the x-axis shows weeks 4, 8, and 12. Error bars indicate standard error for each dose group at each time point.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 14)

An instructional illustration showing a bottle of sildenafil for oral suspension with a cap and syringe adaptor. Next to it is a syringe labeled with tip, barrel, and plunger, marked with 0.5 mL and 2 mL volume indicators for accurate dosing.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 15)

An instructional illustration showing how to prepare a medication suspension from a bottle. The first image depicts shaking the bottle with arrows indicating up, down, and rotational motion. The second image shows a stopwatch timing five seconds. The third image illustrates pressing down and turning the bottle cap to open.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 16)

An instructional illustration showing a hand holding a bottle with an oral syringe being inserted into the bottle opening, indicated by a downward arrow. The syringe is marked with measurement lines to measure liquid dosage accurately.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 17)

An instructional illustration showing a hand holding an inverted medicine bottle attached to a syringe used for measuring liquid medication. The syringe has volume markings indicating 0.5 mL and 2 mL increments. The setup is likely for drawing a dose of oral suspension medicine accurately.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 18)

A black-and-white instructional diagram showing a syringe being pulled upwards from a bottle containing liquid. The image illustrates the initial step in drawing medication from the bottle into the syringe, with a large upward-pointing arrow emphasizing the direction.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 19)

An instructional illustration showing administration of an oral suspension using a syringe, with the tip inside the mouth near the lips. This image likely depicts how to deliver a dose of Sildenafil Citrate 10 mg/mL oral suspension.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 20)

An instructional illustration showing water flowing from a faucet into an oral dosing syringe. The diagram likely represents how to use water to measure or dilute a powder for suspension medication, emphasizing accurate dosing with the syringe.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 21)

Label for Sildenafil for Oral Suspension 10 mg/mL, a powder for suspension by Zydus Pharmaceuticals (USA) Inc. The label includes usage instructions, storage conditions, and volume after reconstitution (112 mL). The product is child-resistant and for oral use only. It is distributed by Zydus Pharmaceuticals USA and manufactured by Cadila Healthcare Ltd., India.*

FDA Label Image

Image (9e802fb6 2a6b 4d5e B292 8a3c31e26076 22)

Box packaging label for Sildenafil for Oral Suspension 10 mg/mL powder for suspension by Zydus Pharmaceuticals (USA) Inc. Contains 112 mL following reconstitution with grape flavor. Includes storage and reconstitution instructions, dosage strength, NDC 70710-1716-4, manufacturer Cadila Healthcare Ltd., India, and distributor details for the USA.*

FDA Label Image

Figure (9e802fb6 2a6b 4d5e B292 8a3c31e26076 23)

Sildenafil Citrate 10 mg/mL oral suspension powder label from Zydus Pharmaceuticals (USA) Inc. The label states the product is for oral suspension, requires shaking before use, and is for oral use only. It includes NDC 70710-1716-5, warnings, storage instructions, and manufacturer information for Cadila Healthcare Ltd., India, and distributor Zydus Pharmaceuticals (USA) Inc.*

FDA Label Image

Figure (9e802fb6 2a6b 4d5e B292 8a3c31e26076 24)

Packaging label for Sildenafil for Oral Suspension 10 mg/mL powder for suspension, oral use, by Zydus Pharmaceuticals (USA) Inc. The label indicates 112 mL after reconstitution, grape-flavored, with dosage and storage instructions, plus a barcode and manufacturer details. NDC 70710-1716-5.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.